Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2055 participants.
Also called NCT03363035
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,055 participants
- Registry
-
NCT03363035
-
- Other papers using this trial's data
- Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial
- U-shaped association between plasma cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) levels and myocardial infarction
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03363035. Randomized; no masking; primary purpose treatment. Start 2018-01-15 (actual); primary completion 2021-11-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
- Acronym
- H-REPLACE
- Condition
- Acute Coronary Syndrome
- Condition
- Myocardial Infarction
- Condition
- Myocardial Ischemia
- Condition
- Unstable Angina
- Intervention (Drug)
- Rivaroxaban 2.5 mg
- Intervention (Drug)
- Rivaroxaban 5 mg
- Intervention (Drug)
- Enoxaparin
- Lead sponsor
- Second Xiangya Hospital of Central South University
Record details
- Record id
cardio:ct-nct03363035- Content hash
0a9930b48fc265f219d265cf607a475600b258a6df5cd1f603fd29042c130539